Početna › Skleroderma › New York
Kliničke studije za Skleroderma u državi New York
11 studija za Skleroderma traži sudionike na lokacijama u državi New York.
Gradovi u državi New York
Službeni tekst studije (engleski)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Hospital for Special Surgery, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center-New York Presbyterian Hospital, New York
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07497087Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- i još 1
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
U tijeku regrutacijaFaza 2/3
Od 18 do 75 godina · Oba spola · Ažurirano 17. kol 2026. · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06733935A Study of AZD0120 in Autoimmune Diseases
- Research Site, New York
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
U tijeku regrutacijaFaza 1
Od 12 do 70 godina · Oba spola · Ažurirano 22. svi 2026. · NCT06308978Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 27. ožu 2026. · NCT03844061Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. svi 2025. · NCT05892614Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.